Company Profile
What's New
Product Information
Applications Info
Tech Reference List
Information Request
Contact Us
Careers
Email Newsletter
Frequently Asked Questions
In Vitro Basics
In Vitro Toxicology Testing (Non-Animal Safety Testing)
Nanoparticle Research Using MatTek Human Tissue Constructs
Site Map
Search




MatTek Corporation
200 Homer Avenue
Ashland, MA  01721
508-881-6771
FAX:  508-879-1532
E-mail Us

Reproducibility Guaranteed!
Front page
Search

EpiAirway™ Performs Well in Inhaled Drug Delivery Experiments

  • A Rapid, Highly Effective, Low Cost Alternative to Expensive Animal and Human Clinical Screens

  • Great Utility as a Primary Screen for Development of Nasal Drug Delivery Vehicles

Evaluation of the Penetration and Cytotoxic Effects of Drug Formulations on an In Vitro Nasal Mucousal Model. J. M. Easow, E. Scotto-Lavino, E. J. Roemer, and S. R. Simon, Department of Pathology, SUNY Stonybrook

The nasal route is an attractive alternative to conventional oral or parenteral drug delivery. The nasal mucosa provides a moist and highly vascularized membrane, crucial to rapid absorption into the blood stream, thus facilitating faster transport to the site of action.

The two main disadvantages of nasal delivery are the limited maximum dose per spray and the rapidity of clearance from the nasal cavity. These difficulties can best be addressed early in drug development. In vitro screening of drug formulations can provide an efficient and cost-effective method of identifying lead candidates prior to in vivo testing.

We have evaluated the ability of a large number of drug formulations to penetrate mucous membranes using MatTek's EpiAirway™ System. The EpiAirway System consists of human derived tracheal/bronchial epithelial cells grown on a collagen coated membrane to form a highly differentiated, organotypic model with many of the same features of nasal mucosa. The cells produce tight junctions that inhibit the passage of low molecular weight solutes, as well as the flow of electric current, permitting the use of trans-epithelial resistance (TER) as a correlate of permeability. Concurrent evaluation of formulation cytotoxicity is important in order to evaluate whether drug permeation is due to a significant loss of viability or if it is occurring on viable tissue constructs. For these studies two complementary systems: lactate dehydrogenase (LDH) release, to measure the accumulation of dead cells, and reduction of tetrazolium salt (MTT), to evaluate the metabolic activity of living cells; were used.

EpiAirway cultures are obtained in phenol red and hydrocortisone free medium and are cultured at 37oC for 48 hours to allow the tissues to equilibrate and begin secreting mucin. Test formulations are applied to the apical surface at the air-tissue interface of quadruplicate tissues. Samples are drawn from the underlying culture medium at 15, 30, 60 and 120 minutes for assay of drug concentration and lactate dehydrogenase (LDH) evaluation of cell death. Following harvest of the final time points, TER of the cell constructs is measured to evaluate tissue integrity. Finally, the viability and relative metabolic activity of each sample tissue is evaluated by cell uptake and transformation of the formazan dye, MTT.

To date we have studied and evaluated the effects of multiple nasal delivery test formulations for a variety of drugs. During the course of screening studies, several of the test articles were run more than once. In each case, the tissue responses were remarkably reliable and reproducible in samples run using different tissue lots. If test formulations incurred any cytotoxic effects, results were consistent across the multiple tissues dosed. Those formulations with evidence of cytotoxic results from LDH and MTT assay data also had significant reduction or loss of tissue resistance. However there were a number of test articles with reduced TER values and increased permeation presenting no cytoxic response.

Overall, this model exhibited a consistent profile of reliability, responding with appropriate sensitivity to test conditions while retaining the characteristics expected of normal tissue and yielding reproducible data, which allowed for the rapid identification of lead candidates for pharmaceutical development.

This study was supported by a NSF-RAIRE grant, No.STI9620074.

Paper Citation and Request Form

EpiAirway Data Sheet

EpiAirway Product Specifications

EpiAirway Technical References

Drug Delivery Research Tools - Recent MatTek Advances


(This abstract originally appeared in the SUNY Stonybrook publication "URECA News", May 2002. Reprinted with permission of E. Roemer, Dept. of Pathology. Bolded text by MatTek Corp. to highlight key points.)


Recent MatTek Press Releases
GlaxoSmithKline's Use of EpiAirway in Cigarette Smoke Exposure Research
ERGECD 2008 European Research Group on Experimental Contact Dermatitis 21st Meeting, 24-26th April 2008 London, UK
Linz 2008 - 15th Congress on Alternatives to Animal Testing
ESTIV 2008 - European Society of Toxicology In Vitro
EUROTOX 2008 45th Congress of the European Societies of Toxicology October 5-8 Rhodes, Greece
In Vitro Model for Allergen Screening using Gene Expression Microarray Technology
The FACTS: EpiDerm and ECVAM - Skin Irritation Validation
EpiAirway Performs Well in Inhaled Drug Delivery Experiments
EpiDerm Approved by EU, U.S. Regulators
MatTek Presentations - ZEBET 20th Anniversary International Symposium
New MatTek Technical References January 2009
EpiDerm™ Excels in European (EC) Standards Study
American Association of Pharmaceutical Scientists (AAPS) - 2008 Meeting Presentations
EpiDerm™ Reproducibility The Best Again!
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2009
New MatTek Technical References February 2010
New MatTek Technical References March 2009
Assessment of Human Skin Irritation: Validation of In Vitro Models
EpiAirway™ - Reproducible Pre-Clinical Drug Development Tool
MatTek Presentations - American Thoracic Society (ATS) 2009 Annual Meeting May 15-20, 2009 San Diego, CA (USA)
New MatTek Technical References April 2009
Drug Delivery Research Tools - Recent MatTek Advances
New MatTek Technical References May 2009
Purified Total RNA
MatTek Presentations - Society for In Vitro Biology (SIVB) Annual Meeting June 2009
New MatTek Technical References June 2009
Wall Street Journal Article - MatTek's Human Tissue Models
MatTek Presentations - 7th World Congress on Alternatives & Animal Use in the Life Sciences (WC7)
New MatTek Technical References November 2009
New MatTek Technical References July 2009
EUROTOX 2009 46th Congress of the European Societies of Toxicology September 13-16 Dresden, Germany
EpiOral™ Excels in P&G Oral Care Formulations Study
New MatTek Technical References September 2009
MatTek Presentation - 2005 ATS Meeting
New MatTek Technical References January 2010
New MatTek Technical References December 2009
New MatTek Technical References October 2009
MatTek Presentations – Society of Toxicology (SOT) Meeting March 2011
MatTek Presentation - American Thoracic Society (ATS) 2006 Annual Meeting May 19-24, 2006 San Diego, CA (USA)
MatTek Presentation - 2006 AAPS National Biotechnology Conference June 18-21, 2006
MatTek Presentations - EUROTOX 2006 September 20-24 Cavtat and Dubrovnik, Croatia
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2007
MatTek Presentation - American Thoracic Society (ATS) 2007 Annual Meeting May 18-23, 2007
MatTek Presentations - 6th World Congress on Alternatives & Animal Use in the Life Sciences (WC6)
Tenth International Workshop on Langerhans Cells
Linz 2007 - 14th Congress on Alternatives to Animal Testing
MatTek Presentations - EUROTOX 2007 October 7-10 Amsterdam, The Netherlands
MatTek Presentation - Photosafety Evaluation of Drugs November 21-22 Amsterdam, The Netherlands
MatTek Presentations - Society of Toxicology (SOT) Meeting March 2008
Asthmatic, Smoker, COPD EpiAirway Tissues
Top